Insider Buying: Kodiak Sciences (NASDAQ:KOD) Director Buys 681,866 Shares of Company Stock

Kodiak Sciences Inc. (NASDAQ:KOD) Director Bros. Advisors Lp Baker acquired 681,866 shares of the firm’s stock in a transaction that occurred on Monday, September 28th. The shares were bought at an average cost of $88.77 per share, for a total transaction of $60,529,244.82. Following the acquisition, the director owned 20,159,386 shares of the company’s stock, valued at $1,789,548,695.22. This represents a 3.50% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Bros. Advisors Lp Baker also recently made the following trade(s):

• On Monday, September 28th, Bros. Advisors Lp Baker acquired 807,840 shares of Kodiak Sciences stock. The shares were bought at an average cost of $72.57 per share, for a total transaction of $58,624,948.80.
• On Monday, September 28th, Bros. Advisors Lp Baker acquired 418,323 shares of Kodiak Sciences stock. The shares were bought at an average cost of $83.58 per share, with a total value of $34,963,436.34.
• On Tuesday, September 29th, Bros. Advisors Lp Baker acquired 33,726 shares of Kodiak Sciences stock. The stock was purchased at an average cost of $85.05 per share, for a total transaction of $2,868,396.30.

Kodiak Sciences Stock Performance

Shares of KOD stock traded up $3.68 on Wednesday, hitting $94.80. The stock had a trading volume of 4,897,441 shares, compared to its average volume of 1,094,203. The stock’s 50 day moving average is $40.26 and its 200-day moving average is $38.27. The firm has a market capitalization of $5.96 billion, a price-to-earnings ratio of -22.63 and a beta of 2.18. Kodiak Sciences Inc. has a 52-week low of $10.94 and a 52-week high of $98.80.

Kodiak Sciences (NASDAQ:KOD) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.96) by ($0.09). Equities analysts expect that Kodiak Sciences Inc. will post -3.89 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in KOD. Algert Global LLC increased its stake in shares of Kodiak Sciences by 26.1% in the 2nd quarter. Algert Global LLC now owns 186,476 shares of the company’s stock valued at $7,265,000 after buying an additional 38,546 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in Kodiak Sciences by 31.8% during the first quarter. The Manufacturers Life Insurance Company now owns 120,629 shares of the company’s stock worth $4,598,000 after buying an additional 29,121 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Kodiak Sciences in the 2nd quarter valued at approximately $1,072,000. Bank of America Corp DE acquired a new stake in Kodiak Sciences in the second quarter worth $14,949,000. Finally, California State Teachers Retirement System lifted its holdings in Kodiak Sciences by 1,358.9% during the first quarter. California State Teachers Retirement System now owns 29,396 shares of the company’s stock worth $1,121,000 after acquiring an additional 27,381 shares in the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $103.00 price objective on shares of Kodiak Sciences in a research note on Wednesday. UBS Group raised their price objective on Kodiak Sciences from $80.00 to $120.00 and gave the stock a “buy” rating in a research report on Monday. JPMorgan Chase & Co. boosted their price objective on shares of Kodiak Sciences from $56.00 to $66.00 and gave the company an “overweight” rating in a research report on Monday, August 3rd. Wall Street Zen lowered shares of Kodiak Sciences from a “sell” rating to a “strong sell” rating in a research note on Saturday. Finally, Lifesci Capital upped their price target on shares of Kodiak Sciences from $85.00 to $145.00 and gave the stock an “outperform” rating in a research note on Monday. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Kodiak Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $100.43.

Key Stories Impacting Kodiak Sciences

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: Kodiak said Zenkuda and tabirafusp-ted achieved the primary endpoints in the Phase 3 DAYBREAK study for wet age-related macular degeneration, reportedly matching Eylea on efficacy while supporting the potential benefits of longer-lasting eye treatments. The results are the main catalyst behind the stock’s sharp increase. KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears
• Positive Sentiment: The company is advancing Zenkuda toward a Biologics License Application filing, strengthening expectations that Kodiak could move from a development-stage biotech toward a commercial product opportunity. Kodiak Sciences Inc. Advances Zenkuda Toward Filing
• Positive Sentiment: HC Wainwright maintained a Buy rating and a $96 price target while raising its long-term EPS forecasts, including estimates of $1.76 for fiscal 2029 and $5.81 for fiscal 2030. It also improved its fiscal 2028 loss estimate, though its fiscal 2027 loss forecast worsened slightly. HC Wainwright Kodiak Sciences analyst estimates
• Positive Sentiment: Additional analyst coverage from Lifesci Capital, UBS Group and HC Wainwright has pointed to higher valuation potential following the clinical update. Kodiak Sciences Stock Gets Price Target Boost from Lifesci Capital
• Neutral Sentiment: Unusually high put-option buying indicates that some traders are hedging or positioning for a pullback after the sharp rally, but it does not by itself establish a fundamental change in the company’s outlook. Kodiak Sciences Stock Sees Unusually High Put Option Buying
• Negative Sentiment: Despite the clinical success, Kodiak remains a cash-burning biotech with no revenue and ongoing development expenses. Analysts and commentators warn that a potential share offering could fund operations but dilute existing shareholders, making the stock’s sharp repricing difficult to chase. A $32 Biotech Became a $90 Biotech Overnight

About Kodiak Sciences

Kodiak Sciences Inc (NASDAQ: KOD) is a biopharmaceutical company focused on developing therapies for retinal diseases and other conditions affecting the eye. The company’s research is centered on antibody biopolymer conjugates, a technology designed to extend the duration of action of biologic medicines in ocular tissues and potentially reduce the frequency of administration.

Its lead development program has been tarcocimab tedromer, also known as KSI-301, an anti-vascular endothelial growth factor (VEGF) therapy investigated for retinal vascular diseases, including diabetic macular edema, diabetic retinopathy and neovascular age-related macular degeneration.